A pan-genotypic HCV NS3/4A protease inhibitor
Voxilaprevir is a pan-genotypic hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) serine protease inhibitor.1 It inhibits replication of wild-type HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a (EC50s = 1.9-6.6 nM in replicon assays). Voxilaprevir also inhibits replication of mutant HCV genotypes containing NS3 resistance-associated substitutions (EC50s = 3.1, 2.7, and 4 nM for HCV genotypes 1a Q80K, 1a R155K, and 1b D168E, respectively). Formulations containing voxilaprevir have been used in the treatment of chronic HCV infection.
1.Taylor, J.G., Zipfel, S., Ramey, K., et al.Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi?Bioorg. Med. Chem. Lett.29(16)2428-2436(2019)
动态评分
0.0